The long-awaited immunization vaccines for SARS-CoV2 have arrived, and for us all to get back to “normal” again, rapid application and sustained large-scale production are required. On them depends to a large extent to achieve recovery and reduce the economic and human impact that Covid-19 is causing.
Generally, vaccines work by exposing to the immune system a virus or part of it, which has been previously weakened or attenuated. When the vaccinated immune system subsequently encounters the real virus, it is already prepared to defend itself. Well, it is worth mentioning that some of the modern vaccines for Covid, such as those provided by Pfizer Inc. and Moderna Inc. use a different and new strategy. It involves introducing instructions (in the form of messenger RNA molecules) into our body to make our cells produce small parts of COVID19 so that the immune system is confronted with them for the first time. This strategy is the first time it has been used to produce vaccines for humans. And, to top it off, it is the first time that all of humanity has to be vaccinated at the same time.
Therefore, when everyone is applauding the efficacy achieved with these vaccines, we have realized that sustaining or multiplying their production requires a supply chain that has never faced this demand before.
Optimizing the entire production chain will not be easy, as there are many gears to synchronize. Some of the suppliers have seen their demands skyrocket to unforeseen levels, for example, the manufacture of glass vials. But in other cases, there are reagents needed in the manufacture of these types of vaccines, such as recombinant enzymes, which have gone from being products manufactured in very small quantities for research laboratories to being needed in much larger volumes.
For this, companies need to dedicate time and investment to scale up the manufacture of these reagents. In addition, these reagents are produced under highly controlled and safe conditions that require validation.
For its part, 53Biologics is an ideal CDMO (Contract Development and Manufacturing Organization) to provide support in this supply chain due to its capacity to optimize and scale up these production processes, as well as for the regular manufacture of this type of recombinant proteins following the highest quality and control standards.